- Published at
- by gurufocus.com
mixed
mixed
News for Oncolytics Biotech Inc. (ONCY)
- Published at
- by gurufocus.com
positivepositiveOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
PR NewswireSAN DIEGO and CALGARY, AB, April 10, 2025 SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS- Published at
- by gurufocus.com
positivepositiveOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital | ONCY Stock News
Oncolytics Biotech (ONCY) secures up to US$20 million funding through a share purchase agreement with Alumni Capital LP. Oncolytics maintains control ov- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
PR NewswireSAN DIEGO and CALGARY, AB, April 10, 2025 SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS- Published at
- by gurufocus.com
negativenegativeOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers | ONCY Stock News
Oncolytics Biotech Inc. (NASDAQ: ONCY) discussed at H.C. Wainwright event for oncolytic immunotherapies in breast and pancreatic cancers. Experts highlighte- Published at
- by seekingalpha.com
negativenegativeOncolytics Biotech Stock: Continuing To Justify The Negativity (NASDAQ:ONCY)
Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh potential rewards.- Published at
- by gurufocus.com
mixedmixedWhy the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/- Published at
- by gurufocus.com
positivepositiveOncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results Amid Financial Challenges
Cash and Cash Equivalents: $15.9 million as of December 31, 2024.Net Cash Used in Operating Activities: $27 million for 2024, compared to $28.4 million for 202- Published at
- by gurufocus.com
positivepositiveQ4 2024 Oncolytics Biotech Inc Earnings Call Transcript
Mar 07, 2025 / 01:30PM GMTOperator Good morning, and welcome to Oncolytics Biotech's fourth-quarter and full-year 2024 conference call. (Operator Instructions)- Published at
- by seekingalpha.com
neutralneutralOncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Results Conference Call March 7, 2025 8:30 AM ETCompany ParticipantsJon Patton - Director of Investor...- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
PR NewswireSAN DIEGO and CALGARY, AB, March 7, 2025 BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful dat- Published at
- by seekingalpha.com
negativenegativeOncolytics Biotech GAAP EPS of -$0.41 misses by $0.10 (NASDAQ:ONCY)
Oncolytics Biotech (ONCY) reports FY GAAP EPS of -$0.41, missing by $0.10. $15.9M cash reserves project runway through Q3 2025.- Published at
- by zacks.com
negativenegativeOncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.- Published at
- by gurufocus.com
mixedmixed- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 25, 2025 Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ETSAN DIEGO and CALGAR- Published at
- by gurufocus.com
negativenegativeOncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 18, 2025 Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy- Published at
- by gurufocus.com
mixedmixedAnson Funds Management LP Acquires Significant Stake in Oncolytics Biotech Inc
Significant Transaction on December 31, 2024 On December 31, 2024, Anson Funds Management LP (Trades, Portfolio) executed a noteworthy transaction by acquiring- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 14, 2025 SAN DIEGO and CALGARY, AB, Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX:- Published at
- by seekingalpha.com
neutralneutralOncolytics Biotech receives Nasdaq non-compliance notice (NASDAQ:ONCY)
Discover how Oncolytics Biotech (ONCY) plans to address Nasdaq's compliance notice for minimum bid price requirements before the August 12, 2025 deadline.- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 7, 2025 Search for Chief Executive Officer to commence immediatelySAN DIEGO and CALGARY, AB, Feb. 7, 2025 /PRNew